Guangyao Group to promote Wang Laoji’s target revenue by RMB 2 billion next year

On the 3rd, Guangpharm Group announced at the "First Healthy China 2020 Summit Forum" that the Group's sales target for the next year will be 50 billion yuan. It also claimed that it will invest 2 billion yuan to promote Wanglaoji brand next year and strive to achieve sales revenue of 10 billion yuan. At present, the Group has reached a cooperation with the fast food brand “real kung fu” and wants to open up chain catering channels. At the same time, Guangpharm Group began to vigorously enter the national drug market and test the water medical market.

According to the Securities Times, with the approval of the Guangzhou Pharmaceutical (600332) restructuring by the China Securities Regulatory Commission, the overall listing of GPHL will enter the actual operation stage. If it goes smoothly, it is expected to achieve overall listing in the first half of next year.

Next year, 2 billion yuan will be promoted by Wanglaoji. "Guangzhou Pharmaceutical Group is gradually forming the "Baiyun Mountain" as the main line to lead Danan Drugs, and "Wang Laoji" as the main line to lead the healthy industrial structure." Li Chuyuan, General Manager of Guangyao Pharmaceutical Group, said that the overall listing was completed. After that, the assets of the entire group will be more complete. "Danan Pharmaceutical" and "big health" two-wheel drive, Guangpharm Group will sprint 50 billion yuan sales target next year, and will achieve 150 billion yuan by 2020, ranking among the world's top 500 companies.

Last year, GP Group achieved a sales target of 33 billion yuan, a year-on-year increase of 20%.

As for the sales situation of Wong Lo Kat, which is concerned about the market, the Group introduced that at present, the distribution of Red Wong Lo Kat has been fully covered in the first-line market, and the second and third-tier markets have been developed in a concentrated manner. The production capacity layout has been basically completed and can meet normal supply. In 2013, GP Group plans to invest RMB 2 billion to vigorously promote the Wanglaoji brand and strive to achieve sales revenue of RMB 10 billion.

On the forum, GP Group also announced that it had reached a strategic cooperation with the first Chinese fast food brand "real kung fu" and put Wong Lo Kat herbal tea into the "real kung fu" stores nationwide. Currently, "real kung fu" has more than 450 stores nationwide, and it is expected to reach 1,000 in 2015.

Entering ethical medicine Since proposing the development strategy of “Danan Pharma”, Guangpharm Group has begun to shift its focus to emerging profit soils, and has made great efforts to enter the national medicine market through aid projects in Xinjiang and Tibet.

In the development of Tibetan medicine, the scientific research cooperation between the Women's Qing Xuelian suppositories carried out by the Guangxi Pharmaceutical Group and the relevant parties in Tibet has obtained the "Approval Document for Clinical Trials of Drugs," which is about to enter Phase III clinical trials; the first high-end health products contain Ganoderma lucidum spore oil, Trial production has begun and preliminary success has been achieved; the Danshen base and Ganoderma base in Bomi County have been started.

In addition, GPHL also plans to acquire Tibetan herbal medicines and understory resources, use the Caizhilin and Jianmin chain pharmacies to set up special sales counters for Tibetan specialty products, and establish a number of characteristic planting bases for Tibetan medicinal herbs.

In terms of Uyghur medicine, GPHL and Kashgar Kunlun Uygur Pharmaceutical Co., Ltd. have conducted equity cooperation and jointly established a joint venture company, and has rapidly expanded Uygur Pharmaceutical's products to the national market through the huge marketing network of GPHL.

Not only that, but also in the test-water medical market, Guangpharm Group will once again make heavy attacks and invest in Baiyinshan medical and medical institutions. This is a cooperation project between the GP Group and the Kashgar Uyghur Hospital, and it is also the first time that GP Group has been involved in the medical field.

According to informed sources, Uighur Hospital in Kashgar has accumulated rich clinical experience in the diagnosis and treatment of vitiligo, and the total effective rate for the treatment of vitiligo in the hospital is currently 98%. It has been listed as the key disease in the "Eleventh Five-year Plan" of the State Administration of Traditional Chinese Medicine. Specialist project unit. Guangyao Pharmaceutical Group plans to use Uyghur Medicine's advantage to extend its pharmaceutical preparations to the national market.